Osimertinib (AZD9291)

For research use only. Not for use in humans.

目录号：S7297 别名： Mereletinib

Osimertinib (AZD9291) Chemical Structure

CAS No. 1421373-65-0

Osimertinib (AZD9291, Mereletinib)是口服不可逆的，突变选择性EGFR抑制剂，在 LoVo细胞中对Exon 19 缺失的 EGFR，L858R/T790M EGFR，和 WT EGFR的IC50分别为12.92，11.44 和 493.8 nM。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1203.93	现货
5mg	RMB 807.34	现货
10mg	RMB 1105.43	现货
100mg	RMB 5733.0	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Osimertinib (AZD9291)发表文献225篇：

Cell, 2020, 182(5):1232-1251.e22

PubMed: 32822576 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1155-63

PubMed: 26286086 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2346

PubMed: 33879767 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108647

PubMed: 33472066 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(5):6890-6903

PubMed: 33621951 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(3):1277-1291

PubMed: 33889509 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):29

PubMed: 33723247 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(6):119016

PubMed: 33744274 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-020-00577-1

PubMed: 33414509 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2021, 419:115518

PubMed: 33812963 ( click the link to review the publication )

Thorac Cancer, 2021, 10.1111/1759-7714.13931

PubMed: 33710795 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(1):128-142

PubMed: 33569299 ( click the link to review the publication )

Lung Cancer, 2021, 154:84-91

PubMed: 33631449 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):32

PubMed: 33863983 ( click the link to review the publication )
Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w

PubMed: 33686255 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Sci Immunol, 2020, 31;5(43) pii: eaav3937

PubMed: 32005679 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2321

PubMed: 31953310 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Theranostics, 2020, 15;10(14):6122-6135

PubMed: 32483443 ( click the link to review the publication )

Cancer Res, 2020, 80(21):4655-4667

PubMed: 32873635 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 28;483:46-58

PubMed: 32272148 ( click the link to review the publication )

Cancers (Basel), 2020, 13(1)E111

PubMed: 33396393 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32183160 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Hum Mol Genet, 2020, ddaa268

PubMed: 33326033 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Lung Cancer, 2020, 5;145:48-57

PubMed: 32408132 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0664

PubMed: 33106373 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16135

PubMed: 33247550 ( click the link to review the publication )
Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):366

PubMed: 32355810 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22899

PubMed: 31916386 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 534:1-7

PubMed: 33302159 ( click the link to review the publication )

J Oncol, 2020, 17;2020:6249829

PubMed: 32256584 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):169

PubMed: 33287873 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Nat Cancer, 2020, 1(3):359-369

PubMed: 33345196 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:652

PubMed: 32793596 ( click the link to review the publication )

Pharmaceutics, 2020, 12(10)E939

PubMed: 33008019 ( click the link to review the publication )

Cells, 2020, 9(12)E2596

PubMed: 33287368 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0443-1

PubMed: 32704041 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0457-8

PubMed: 32678313 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11236

PubMed: 32641854 ( click the link to review the publication )

Food Funct, 2020, 11(3):2714-2724

PubMed: 32163057 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(4):656-671

PubMed: 30578931 ( click the link to review the publication )
Clin Cancer Res, 2019, 25(11):3329-3340

PubMed: 30770351 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz206

PubMed: 31678994 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Syst, 2019, 10.1016/j.cels.2019.10.002

PubMed: 31668800 ( click the link to review the publication )

Biomaterials, 2019, 219:119400

PubMed: 31398570 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2808

PubMed: 31806641 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(5):656-670

PubMed: 30171258 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers, 2019, 11(3)

PubMed: 30818860 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):112-126

PubMed: 30322949 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1593-1601

PubMed: 31253648 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Lung Cancer, 2019, 127:146-152

PubMed: 30642543 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(11):7427-7437

PubMed: 31454149 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(12):2607-2614

PubMed: 31754333 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )
Cancer Manag Res, 2019, 11:3419-3432

PubMed: 31114376 ( click the link to review the publication )

Ann Transl Med, 2019, 7(22):651

PubMed: 31930052 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 379:114662

PubMed: 31301315 ( click the link to review the publication )

J Cell Biochem, 2019, 120(1):756-767

PubMed: 30145802 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

Thorac Cancer, 2019, 10(10):1868-1878

PubMed: 31486270 ( click the link to review the publication )

Breast Cancer (Dove Med Press), 2019, 11:231-241

PubMed: 31839713 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):955-961

PubMed: 31289574 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(10):1689-1704

PubMed: 31314158 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 7(1):161-184

PubMed: 30522949 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5692

PubMed: 30952931 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2019, 22(5):264-270

PubMed: 31109435 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4655

PubMed: 30405134 ( click the link to review the publication )

J Thorac Oncol, 2018, 13(7):915-925

PubMed: 29702287 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(22):5610-5621

PubMed: 29967248 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )
Cancer Res, 2018, 10.1158/0008-5472.CAN-18-0505

PubMed: 30026325 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):740-750

PubMed: 29467275 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2257-2265

PubMed: 30049789 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(1):99-109

PubMed: 29269566 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Cell Neurosci, 2018, 12:21

PubMed: 29456493 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(3):239-247

PubMed: 29333953 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 10.1007/s00432-018-2668-7

PubMed: 29797219 ( click the link to review the publication )

Cancer Med, 2018, 7(1):208-218

PubMed: 29239135 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Environ Toxicol, 2018, 33(11):1153-1159

PubMed: 30136359 ( click the link to review the publication )

Radiat Res, 2018, 189(3):283-291

PubMed: 29332537 ( click the link to review the publication )

Pharmazie, 2018, 73(11):630-634

PubMed: 30396380 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

JCI Insight, 2018, 3(24)

PubMed: 30568033 ( click the link to review the publication )
JCI Insight, 2018, 3(11)

PubMed: 29875309 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

Oncotarget, 2018, 9(76):34240-34258

PubMed: 30344940 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Sci Transl Med, 2017, 9(415)

PubMed: 29118262 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

J Natl Cancer Inst, 2017, 1;109(9):djx014

PubMed: 28376152 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(5):884-889

PubMed: 28088511 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Neuro Oncol, 2017, 19(12):1628-1639

PubMed: 28575494 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3527-3539

PubMed: 28522751 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472

PubMed: 28202511 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1200-1211

PubMed: 28082405 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.21536

PubMed: 28199182 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(2):357-364

PubMed: 27913578 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(3):506-515

PubMed: 28138027 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Mol Oncol, 2017,

PubMed: 28388009 ( click the link to review the publication )

J Mol Biol, 2017, 429(14):2211-2230

PubMed: 28539250 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:510-527

PubMed: 28987609 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):915-928

PubMed: 28289161 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(11):1542-1550

PubMed: 28784613 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):852-861

PubMed: 28314843 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

Lung Cancer, 2017, 108:96-102

PubMed: 28625657 ( click the link to review the publication )

Lung Cancer, 2017, 109:1-8

PubMed: 28577937 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Clin Lung Cancer, 2017, 18(3):281-285

PubMed: 28038979 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 321:18-26

PubMed: 28237877 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5281-5288

PubMed: 29138581 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

J Vis Exp, 2017, (126)

PubMed: 28829429 ( click the link to review the publication )

Oncotarget, 2017, 8(62):105479-105491

PubMed: 29285266 ( click the link to review the publication )

Oncotarget, 2017, 8(41):70736-70751

PubMed: 29050315 ( click the link to review the publication )
Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36331-36338

PubMed: 28422737 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109319-109331

PubMed: 29312610 ( click the link to review the publication )

Oncotarget, 2017, 8(62):104894-104912

PubMed: 29285221 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15441

PubMed: 29133857 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Mol Cell, 2016, 63(3):526-38

PubMed: 27453044 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

Cancer Immunol Res, 2016, 4(11):936-947

PubMed: 27680026 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.216

PubMed: 27345413 ( click the link to review the publication )

J Med Chem, 2016, 59(13):6187-200

PubMed: 27266526 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):3040-3054

PubMed: 27612490 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23608-32

PubMed: 27015562 ( click the link to review the publication )

Sci Rep, 2016, 6:37997

PubMed: 27897231 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )
Clin Cancer Res, 2015, 21(23):5305-13

PubMed: 26206867 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Sci Signal, 2015, 8(379):ra53

PubMed: 26038598 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6589-606

PubMed: 26258521 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143333

PubMed: 26580964 ( click the link to review the publication )

J Natl Compr Canc Netw, 2013, 11(10):1249-61

PubMed: 24142826 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )

Expert Opin Pharmacother, 2010, 11(8):1263-76

PubMed: 20429667 ( click the link to review the publication )

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

特性

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

靶点

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

体外研究

与体外野生型相比，在突变EGFR 细胞系中AZD9291能更有效的抑制增殖。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC-9/BRc1	NYjGU4tpTnWwY4Tpc44hSXO\|YYm=	MYe1NEBvVQ>?	MWGyOEBp	MoHnSG1UVw>?	NWrCdphFcW6mdXPld{BmgHC{ZYPzbY9vKG:oIITo[UBxem:jcH;weI91cWNiQlPMMVIh\mGvaXz5JI1mdWKncjDCTW0>	NVjsZo5lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/ERc1	NHz3WFdHfW6ldHnvckBCe3OjeR?=	NXKycWR7PTBibl2=	NXixZZFwOjRiaB?=	MULEUXNQ	M3GzT4lv\HWlZYOg[ZhxemW\|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN	NYrObm5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
VP-2	NVLZcmtFTnWwY4Tpc44hSXO\|YYm=	NH3EXZk2OCCwTR?=	NHm1Z\|YzPCCq	NHq0SZJFVVOR	M1PPN4lv\HWlZYOg[ZhxemW\|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN	MoLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
PC-9/BRc1	NX;qfpplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvLO5dKPTBibl2=	MUGxNEBl	MofRSG1UVw>?	Ml;ibY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm\|	NE\WVVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
PC-9/ERc1	NWL0botzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moi5OVAhdk1?	NWLPfIZGOTBiZB?=	NWi3PIFzTE2VTx?=	M{PMVIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?=	MnK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
VP-2	M2X5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP3c2Y2OCCwTR?=	MUKxNEBl	NIn5WJFFVVOR	M{XCVolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?=	NGnCW\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
PC9 GR4	NXPUdoxCTnWwY4Tpc44hSXO\|YYm=	M4DMeFAuOTBizszN	NYrDVJdDPzJiaB?=		M2W1fIlvcGmkaYTzxsBGT0[UIIDoc5NxcG:{eXzheIlwdiCjbnSg[I94dnO2cnXhcUB{cWewYXzpcofDqA>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2OE[zN{c,OjV7NEi2N\|M9N2F-
PC9	NHXzeHFHfW6ldHnvckBCe3OjeR?=	MknNNE0yOCEQvF2=	MlXNO\|IhcA>?		M2LTcIlvcGmkaYTzJHdVKEWJRmKgZZQhdG:5IHPvcoNmdnS{YYTpc45{	MoHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
PC9 GR4	Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v2SlAuOTBizszN	NHrzZmU4OiCq		M2H5ZolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	NEnYZ5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0PFY{Oyd-MkW5OFg3OzN:L3G+
BAF3	MXzGeY5kfGmxbjDhd5NigQ>?		NHPuNHg4OiCq		M4H0ZmdKPTBiPTCwMlAxODNizszN	NGnoNJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NXrWVoNkTnWwY4Tpc44h[XO\|YYm=		M2S3dFczKGh?		NVHw[I9ST0l3MDC9JFAvODByMzFOwG0>	NF[0S2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NIfGVFlHfW6ldHnvckBie3OjeR?=		NGnuSnQ4OiCq		NXzNcYtuT0l3MDC9JFAvODBzIN88US=>	NUHtWmJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	M{nMNWZ2dmO2aX;uJIF{e2G7		MYK3NkBp		NIOwNHFIUTVyIE2gNE4xODFizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9	M2S2fGZ2dmO2aX;uJIF{e2G7		NFnuTnY4OiCq		NGjaPY5IUTVyIE2gNE4xODJizszN	NY[zO3BMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	M1f0OWZ2dmO2aX;uJIF{e2G7		MV60JIg>		NUL4e\|NGTUN3MDC9JFAvODB{IN88US=>	NFewd2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	MVTGeY5kfGmxbjDhd5NigQ>?		NX\NfVRsOyCq		MVfJR\|UxKD1iMD6wNFI2KM7:TR?=	M{HIW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN\|gzQTxxYU6=
H1975	NH7adYtHfW6ldHnvckBie3OjeR?=		Ml21N{Bp		NWC4OWRVUUN3MDC9JFAvODB{NTFOwG0>	NG\5V5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
H3255	MnTJSpVv[3Srb36gZZN{[Xl?		NYDFcJlQOyCq		NWm1eGlOUUN3MDC9JFAvODB2MTFOwG0>	NGe2Z3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
NCI-H1975	MojNSpVv[3Srb36gZZN{[Xl?		NHvDcGs4OiCq		MkHpS2k2OCB;IECuNFA2KM7:TR?=	M4f2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
PC9	MmX0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MnnIO\|IhcA>?		MYDJR\|UxKD1iMD6wNFY2KM7:TR?=	M4fl[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
NCI-H1975	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NEC2cVE4OiCq		M1HnXWlEPTBiPTCwMlAyODVizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
Sf21	NEP6N3ZHfW6ldHnvckBie3OjeR?=				M1nnRWlEPTBiPTCwMlAyOiEQvF2=	NWXIOI9GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVYzPjdpPkK3PVk3OjZ5PD;hQi=>
PC9-DRH	MlzKSpVv[3Srb36gZZN{[Xl?		M3;6RVIhcA>?		MkHjTWM2OCB;IECuNFE{KM7:TR?=	NIG5VJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
BAF3	MX3GeY5kfGmxbjDhd5NigQ>?		MljBO\|IhcA>?		MmniS2k2OCB;IECuNFE{KM7:TR?=	NWHaUmNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	MlL0SpVv[3Srb36gZZN{[Xl?		M1H5SFk3KGh?		MXHFR\|UxKD1iMD6wNVQh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
HCC827	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M1vsfVk3KGh?		MoP5SWM2OCB;IECuNFE1KM7:TR?=	NXTtO2pWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
NCI-H1975	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MXy5OkBp		MlfVSWM2OCB;IECuNFE1KM7:TR?=	NGnsOmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	M4\RVGZ2dmO2aX;uJIF{e2G7		M1zGb\|IhcA>?		M1fj[WlEPTBiPTCwMlAyPSEQvF2=	NUi1dog3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
H1975	M37uSGZ2dmO2aX;uJIF{e2G7		NHPERXEzKGh?		NXS3dJRCUUN3MDC9JFAvODF3IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
PC9	MnXvSpVv[3Srb36gZZN{[Xl?		MkjNNkBp		M4DCVWlEPTBiPTCwMlAyPyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
NCI-H1975	MkPNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NHW4dGI4OiCq		MXjJR\|UxKD1iMD6wNVkh\|ryP	MlHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
NCI-H1975	NXrqS2V4TnWwY4Tpc44h[XO\|YYm=		MYq5OkBp		M1TqOmVEPTBiPTCwMlAyQSEQvF2=	M1W5WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
NCI-H1975	M13oN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MkPBPVYhcA>?		MWTFR\|UxKD1iMD6wNVkh\|ryP	MojvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4MEO5PVEoRjJ6NkCzPVkyRC:jPh?=
NCI-H1975	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MlzGO\|IhcA>?		MoXVTWM2OCB;IECuNFE6KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
HCC827	MoK5SpVv[3Srb36gZZN{[Xl?		MWmyJIg>		MmjJTWM2OCB;IECuNFI{KM7:TR?=	NFfsUXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975	MofPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MYe3NkBp		Mnm4TWM2OCB;IECuNFI{KM7:TR?=	NGXkbXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
PC9	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		NGP5SI04OiCq		MW\HTVUxKD1iMD6wNlMh\|ryP	NIiwSW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
NCI-H1975	NILQ[pREgXSxdH;4bYNqfHliYYPzZZk>		NF7FWYs4OiCq		M4\JZmdKPTBiPTCwMlAzPCEQvF2=	NG\Xfm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
HCC827	M2PmdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3:yTlczKGh?		NVW5Tms4UUN3MDC9JFAvODJ3NDFOwG0>	NVG0bXFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
HCC827	M{jHU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M4nHelczKGh?		MnLnTWM2OCB;IECuNFI4KM7:TR?=	MljMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
HCC827	NVq2SXJFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NEjES5c4OiCq		MnmxTWM2OCB;IECuNFI4KM7:TR?=	NVHwWlRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
NCI-H1975	NYTub\|dGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MknUO\|IhcA>?		M3vVZWlEPTBiPTCwMlA{KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|M{W3PUc,OjhyM{O1O\|k9N2F-
H3255	M3ftbGZ2dmO2aX;uJIF{e2G7		NGLOTmI4OiCq		MmLWS2k2OCB;IECuNFM{KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255	M2nMSmZ2dmO2aX;uJIF{e2G7		MV6yJIg>		NVr4Z4VXUUN3MDC9JFAvODN4IN88US=>	NVS1bVRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
NCI-H1975	MmnXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M{\zT\|czKGh?		M2HCUWlEPTBiPTCwMlA1OSEQvF2=	MnnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5M{CxPVIoRjJ7N{OwNVkzRC:jPh?=
NCI-H1975	M{CwU2Z2dmO2aX;uJIF{e2G7		NGDmSHUyKGh?		NHj0WFNKSzVyIE2gNE4xPDFizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmyOkc,Ojl3M{S5NlY9N2F-
BAF3	M3T0VWZ2dmO2aX;uJIF{e2G7		Mn\WOEBp		M4DROWVEPTBiPTCwMlA1OyEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	NVLp[4JQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		Mnf3O\|IhcA>?		NX;LTGN4UUN3MDC9JFAvODR5MjFOwG0>	M3rYTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
NCI-H1975	M4\GVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NIPYS2I4OiCq		MYPJR\|UxKD1iMD6wOVIh\|ryP	NGnFVmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVY{QSd-MkexN\|E3Ozl:L3G+
PC9	NVTKbWp7TnWwY4Tpc44h[XO\|YYm=		MV:yJIg>		NXmz[Yt6UUN3MDC9JFAvODV4IN88US=>	NWW4[FA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
NCI-H1975	Mlz1R5l1d3SxeHnjbZR6KGG\|c3H5		Mo\vO\|IhcA>?		NEX5UmdKSzVyIE2gNE4xPiEQvF2=	M4[1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU{Lz5{OUS4Olk2OzxxYU6=
HCC827	MlLCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				NULROHdlUUN3MDC9JFAvODZzNjFOwG0>	NI\COpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
NCI-H1975	M4TCfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				NHTze5pKSzVyIE2gNE4xPjdizszN	NU\keHRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
HaCaT	M17kVmZ2dmO2aX;uJIF{e2G7		NI\BPJE{KGh?		MnrwTWM2OCB;IECuNFc{PyEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
NCI-H1975	MmPqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MkjtO\|IhcA>?		MX;JR\|UxKD1iMD6xN{DPxE1?	NEHlXJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
A431	NXrSUZdXTnWwY4Tpc44h[XO\|YYm=		M{LQ[lEhcA>?		MYTJR\|UxKD1iMD6xOFEh\|ryP	Moq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
A549	NHfqTIRHfW6ldHnvckBie3OjeR?=				MnTwTWM2OCB;IECuNVUh\|ryP	NEXuSYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
Calu3	NYfKPZBpS3m2b4TvfIlkcXS7IHHzd4F6		MXu3NkBp		M13ESGdKPTBiPTCwMlI3PCEQvF2=	NHuzNHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
Sf9	MVvGeY5kfGmxbjDhd5NigQ>?		NXPVZ3o2OjBibXnudy=>		NEPXOXhKSzVyIE2gNE4zPzhizszN	MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OEKxOVEoRjJ6NEiyNVUyRC:jPh?=
BAF3	NWjUc\|ZqTnWwY4Tpc44h[XO\|YYm=		MWO3NkBp		NX\yS4VnT0l3MDC9JFAvOyEQvF2=	M123PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	NUiw[WxbTnWwY4Tpc44h[XO\|YYm=		MYK3NkBp		MWHHTVUxKD1iMD6zNUDPxE1?	MmHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H460	M3PRXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MV63NkBp		M2njc2lEPTBiPTCwMlQyPTlizszN	NFzzeXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOlY1OSd-Mki3NVY3PDF:L3G+
LoVo	NH;VbmxHfW6ldHnvckBie3OjeR?=		NUTL[VlKOiCq		MoTQTWM2OCB;IECuOFgh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo	MlfFSpVv[3Srb36gZZN{[Xl?		MmPwNkBp		MnvRTWM2OCB;IECuOFgh\|ryP	MnfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OU[yOlcoRjJ5OUm2NlY4RC:jPh?=
A549	NHTUW3FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NFLJbW84OiCq		NWHRVG1uUUN3MDC9JFAvPDh4IN88US=>	M37PUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3	NXPNeGdzTnWwY4Tpc44h[XO\|YYm=		MXu3NkBp		NXHrcFNGT0l3MDC9JFAvPSEQvF2=	M3:zTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A549	NWPKSol{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NUPNOYpFPzJiaB?=		NXn1fW4xUUN3MDC9JFAvPTNizszN	NESyVnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
A549	M{O0XGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NX;tO\|hFPzJiaB?=		MVXJR\|UxKD1iMD61N{DPxE1?	NHzBR3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
BAF3	NXTtbZdxTnWwY4Tpc44h[XO\|YYm=		MX63NkBp		NEL4fVdIUTVyIE2gNE42PSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	NED3VGpHfW6ldHnvckBie3OjeR?=		Mnn1O\|IhcA>?		NF3r[XJIUTVyIE2gNE42PiEQvF2=	MkP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HEK293	MnnoSpVv[3Srb36gZZN{[Xl?				Ml3xTWM2OCB;IECuOVch\|ryP	NUHueIRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
BAF3	NEDFXHBHfW6ldHnvckBie3OjeR?=		MUO3NkBp		MVjHTVUxKD1iMD61PUDPxE1?	NFrMS5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A431	MljyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				MlvnTWM2OCB;IECuOlE2PiEQvF2=	M1nab\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
HT-29	NILSPGxEgXSxdH;4bYNqfHliYYPzZZk>		MnzlO\|IhcA>?		NHLzZ\|FKSzVyIE2gNE43PSEQvF2=	M3vZ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU{Lz5{OUS4Olk2OzxxYU6=
A431	MofNSpVv[3Srb36gZZN{[Xl?		Mo\DPVYhcA>?		MkXYSWM2OCB;IECuOlY4KM7:TR?=	M4j4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
A431	NG\V[o9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1P2Rlk3KGh?		NET3XHdGSzVyIE2gNE43PyEQvF2=	NXjifYhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
A431	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NV\rNVBsPzJiaB?=		M3ftTGlEPTBiPTCwMlY5PSEQvF2=	M{Hn[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVI3Lz5{OUWzOFkzPjxxYU6=
A431	NFHSVWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M2D5[lk3KGh?		M{jhZmVEPTBiPTCwMlch\|ryP	Mo\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4MEO5PVEoRjJ6NkCzPVkyRC:jPh?=
A549	NIPCUXFEgXSxdH;4bYNqfHliYYPzZZk>		M3njVVczKGh?		NE\4Z4RKSzVyIE2gNE45PyEQvF2=	Mlu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
A431	NFfDR3hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NHXac444OiCq		MlTwTWM2OCB;IECuPFk{KM7:TR?=	Mmq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{G2N\|koRjJ5MUOxOlM6RC:jPh?=
BA/F3	MojERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MV[3NkBp		NXOzdW9nUUN3MDC9JFEh\|ryP	MknhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
BAF3	M2rGVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1\CR\|czKGh?		NHLqbGlIUTVyIE2gNU4zKM7:TR?=	NX\XV4NNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H2122	NXy2OpM1TnWwY4Tpc44h[XO\|YYm=		NVPnPJBzPzJiaB?=		M4nUdmdKPTBiPTCxMlIh\|ryP	NFnnS3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A431	M3PMeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M{TOOFczKGh?		M1rYW2lEPTBiPTCxMlI1KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NYnhbmVjPzJiaB?=		MnnmTWM2OCB;IEGuNlYh\|ryP	M33CSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
A431	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MYG3NkBp		M2HSWWlEPTBiPTCxMlYxPCEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|M{W3PUc,OjhyM{O1O\|k9N2F-
A549	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NEjSRpM6PiCq		NX24dVlHTUN3MDC9JFEvQDNizszN	M1;4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
CHL	MlP6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYGwb2oxPzJiaB?=		MmHpS2k2OCB;IEKuPUDPxE1?	M1TYcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H1355	NXu0fYV5TnWwY4Tpc44h[XO\|YYm=		NWX2eJREPzJiaB?=		M1HNWGdKPTBiPTCzJO69VQ>?	MoXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1703	NH:1PVVHfW6ldHnvckBie3OjeR?=		NGTSXXU4OiCq		NG\KW\|dIUTVyIE2gN{42KM7:TR?=	MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A549	MWPGeY5kfGmxbjDhd5NigQ>?		M1PSVVczKGh?		MkLyS2k2OCB;IEOuOUDPxE1?	NWHJTJRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
CHO	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWmwNFVkPzJiaB?=		M1vmXGdKPTBiPTC0MlIh\|ryP	NIWwcIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NHnh[5hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		Mk[4O\|IhcA>?		M1vUOmlEPTBiPTC0MlYyKM7:TR?=	NWj3Z252RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BAF3	NFvTTHhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M{\1R\|czKGh?		M3LsZmlEPTBiPTC1MlE2KM7:TR?=	M1fUd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
BEAS2B	M4DSc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M{W2RVczKGh?		M2r5eGlEPTBiPTCxOE46KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975	MoPzSpVv[3Srb36gZZN{[Xl?		MUOyJIg>		NWP6UZFpUUN3MDC9JFE2KM7:TR?=	NYjWT29PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
PC9	M3;pfWZ2dmO2aX;uJIF{e2G7		NWL3VlFSOiCq		M1z5bGlEPTBiPTCxO{DPxE1?	NWmzepdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
LoVo	NVLVU5IzTnWwY4Tpc44h[XO\|YYm=		MkPQNkBp		MkHUTWM2OCB;IES4NEDPxE1?	M4nJSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975	NWD4TIp{SW62aYT1cY9zKGGldHn2bZR6KGG\|c3H5				NFu0OlhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFk4OE1iZH;1ZoxmKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDJwNTDt[{9s\y:mYYmsJJBwKHGmIH\vdkA4KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=>	M{fDcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
rat hepatocytes	M3f1XWZ2dmO2aX;uJIF{e2G7				NE\Odm9KdnS{aX7zbYMh[2ynYYLhcoNmKGmwIILheEBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=>	NEXHeng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
human hepatocytes	NInpc2JHfW6ldHnvckBie3OjeR?=				MorSTY51emmwc3njJINt\WG{YX7j[UBqdiCqdX3hckBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	MWnBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				MWTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEm3NG0h\G:3YnzlJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	NI\wR2ZHfW6ldHnvckBie3OjeR?=				NGrIS3pU\WynY4Tpeol1gSCrbnTlfEwhemG2aX:gc4YhUUN3MDDmc5IhTUeIUjDUO\|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHSxIFnDOVAh\m:{IIfpcIQhfHmyZTDFS2ZTKGW6cILld5NqdmdiaIXtZY4hSTR\|MTDj[Yxtew>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
NCI-H1975	MVPBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				MkTWRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWiCWN{mwUU9NQDV6UjDkc5VjdGVibYX0ZY51KGW6cILld5NqdmdiaIXtZY4hVkOLLVixPVc2KGOnbHzzJJhmdm:pcnHmeIVlKGmwIFLBUGIw[yCjdHj5cYlkKG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNVAhdWdxa3esJJBwKGKrZDDmc5IhOjFiZHH5dy=>	NFjWOW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N\|AyQTJ:L3G+
HCC827	M{jsTmFxd3C2b4Ppd{Bie3OjeR?=				MYfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCHN{S2MWE4PTBiZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IHXhdox6KGGyb4D0c5Rq[yClZXzsd{BifCB\|IIXNJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[tSmlVSy:ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7IDjSeoIhRSBzLkO0KUk>	NEfZ[Ik9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
HCC827	Mne2RZBweHSxc3nzJIF{e2G7				NUnWS4FLUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1Pi2DN{WwJIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{Bt[XSnIHHwc5B1d3SrYzDj[YxteyCjdDCzJJVOKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYuTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5JEhTfmJiPTCyO{4yPCVr	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
A549	M{DoRWZ2dmO2aX;uJIF{e2G7				MWnT[Yxm[3Srdnn0fUBz[XSrbzDv[kBKSzVyIH\vdkBpfW2jbjDBOVQ6KGOnbHzzJIV5eHKnc4Ppcochf2muZD30fZBmKEWJRmKvT{1T[XNibYX0ZY51KHSxIFnDOVAh\m:{IHj1cYFvKE6FST3INVk4PSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdB?=	NELUdFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
HCC827	NXPERVl6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NUTBbW5kPzJiaB?=		NHvZTnRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|gzPyClZXzsd{BifCBzIIXNJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	NYjIO3V6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
BAF3	NWPub2t1TnWwY4Tpc44h[XO\|YYm=		MX:yJIg>		M4TP[GlvcGmkaYTpc44hd2ZiRVfGVkBVPzlyTT;MPFU5Wi:FN{m3V{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHNWmwZIXj[YQhemWlZYD0c5IheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gN{B2VSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M133VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
BAF3	NFvZbYRHfW6ldHnvckBie3OjeR?=		NHrSO2kzKGh?		NVvrT5RxUW6qaXLpeIlwdiCxZjDFS2ZTKDF7RD;UO\|kxVS:FN{m3V{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHNWmwZIXj[YQhemWlZYD0c5IheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gN{B2VSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
NCI-H1975	MYLBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				MnXRRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHinbn;ndoFnfGWmIHnuJHNVV0ONLV\vfI4ydnVxTnr1JI52\GVibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDndo94fGhiYYSgNlAhdWdxa3ev[IF6NCCybzDx[EBnd3JiMUSg[IF6eyC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?=	NVHKc3VoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizPVUzOTlpPkK4N\|k2OjF7PD;hQi=>
Caco2	MlKzSpVv[3Srb36gZZN{[Xl?		NIDL[4czKGh?		MmD5SYZndHW6IILheIlwKG:oIHHwdIFz\W62IIDldo1m[WKrbHn0fUBnem:vIHLhd49t[XSncnHsJJNq\GVidH:gZZBq[2GuIIPp[IUhd3[ncjDhdIlk[Wxic3nk[UB1dyCkYYPvcIF1\XKjbDDzbYRmKG:4ZYKgbY4hcHWvYX6gR4FkdzJiY3XscJMh[XRiNTD1UUBqdmO3YnH0[YQh\m:{IEKgbJJ{	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
A431	MlewSpVv[3Srb36gZZN{[Xl?				MVrT[Yxm[3Srdnn0fUBz[XSrbzDv[kBGSzVyIH\vdkBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKgeI8hTUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTNUx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
Caco2	MnfMSpVv[3Srb36gZZN{[Xl?		MoW5NkBp		NFzyTJRCeHCjcnXueEBx\XKvZXHibYxqfHliYXPyc5N{KGGyaXPhcEB1dyCkYYPvcIF1\XKjbDDzbYRmKGmwIHj1cYFvKEOjY3:yJINmdGy\|IHH0JFUhfU1iaX7jeYJifGWmIH\vdkAzKGi{cx?=	NXu5ZmpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
Caco2	MYrGeY5kfGmxbjDhd5NigQ>?		NETnfnQzKGh?		MVLBdJBiemWwdDDw[ZJu\WGkaXzpeJkh[WO{b4PzJIJie2:uYYTldoFtKHSxIHHwbYNidCC\|aXTlJIlvKGi3bXHuJGNi[29{IHPlcIx{KGG2IEWgeW0hcW6ldXLheIVlKG[xcjCyJIhzew>?	NHvvXVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	M2fJNWZ2dmO2aX;uJIF{e2G7		NWfRW4l4PCCq		Mlq2TY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFHreEBxcG:\|cHjvdplt[XSrb36gZZQhXGi{M{C4M3NmejR5MzDzbZRmKGG2IEGgeW0hdWWjc4Xy[YQh[W[2ZYKgOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NHLuW5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	NY\reYdITnWwY4Tpc44h[XO\|YYm=		M4HiOVQhcA>?		MojuTY5pcWKrdHnvckBw\iCHR1\SJIV5d25iMUmg[IVt\XSrb36gcZV1[W62IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRYt1KHCqb4PwbI9zgWyjdHnvckBifCCWaIKzNFgwW2W{NEezJJNqfGViYYSgNUB2VSCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	MUDBdI9xfG:\|aYOgZZN{[Xl?		M{jUSVQ5KGh?		NVnNUYtLUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KGG\|c3Xzd4VlKGG\|IHPhd5Bie2V\|IHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	NXXqfJJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	M2r0eWFxd3C2b4Ppd{Bie3OjeR?=		NFrIRZA1QCCq		MkTQTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCvdYThcpQh[XO\|ZYPz[YQh[XNiY3HzdIF{\S1\|IHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	NYfrc\|d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	MnvjRZBweHSxc3nzJIF{e2G7		NITWemU1QCCq		M2PF[Glv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	NWXwNotSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H3255	NEPkb5lCeG:ydH;zbZMh[XO\|YYm=		NYjJN4dvPDhiaB?=		M33qSmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSEOyOVUh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIhdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	M17GdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	MVHBdI9xfG:\|aYOgZZN{[Xl?		M2rWOVQ5KGh?		NIKyTJFKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>?	NYey[5YyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	Mkm2RZBweHSxc3nzJIF{e2G7		NHPSPI81QCCq		MVvJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFCFOTDj[YxteyCqYYLic5JqdmdiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	NVHZNXZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	MUjBdI9xfG:\|aYOgZZN{[Xl?		NXW5[HAxPDhiaB?=		M3HZdGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IGDBVnAh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	M17yV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255	MlXMRZBweHSxc3nzJIF{e2G7		M3npelQ5KGh?		NEHEVWFKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFizNlU2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975	NWfS[nE2TnWwY4Tpc44h[XO\|YYm=				NUPEfIVuW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iQUSzNUBk\WyuczDoZZJjd3Krbnege4lt\C22eYDlJGVITlJ?	MlPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
human hepatocytes	MV7GeY5kfGmxbjDhd5NigQ>?				M{fVUmlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5iaIXtZY4hcGWyYYTvZ5l1\XNiYYPz[ZN{\WRicHXyJI1qdGyrb36gZ4VtdHN?	NUDDdXNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
rat hepatocytes	NUD1d3hUTnWwY4Tpc44h[XO\|YYm=				M1rteGlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5icnH0JIhmeGG2b3P5eIV{KGG\|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
A549, NCI-H1975	MnvpSpVv[3Srb36gZZN{[Xl?				NY\rXmtMW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiRVfGMZN1cW23bHH0[YQhf2muZDD0fZBmKEWJRmKgbY4hcHWvYX6gRVU1QSClZXzsd{B1dyCLQ{WwJIZweiCHR1\SJGw5PTiUL2S3PVBOKGSxdXLs[UBufXSjboSgbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy\|	NF;Xc\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
A549, PC9	NWjTe4xsTnWwY4Tpc44h[XO\|YYm=				NEC5bXRU\WynY4Tpeol1gSC{YYTpc{Bw\iCLQ{WwJIZweiCHR1[td5RqdXWuYYTl[EB4cWymIIT5dIUhTUeIUjDpckBpfW2jbjDBOVQ6KGOnbHzzJJRwKEmFNUCg[o9zKEWJRmKg[IVt\XSrb36gcZV1[W62IHnuJIh2dWGwIGDDPUBk\Wyucx?=	M1q2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
HCC827	NFLvdIVCeG:ydH;zbZMh[XO\|YYm=				M1XBRmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYhfG9iQUe1NEBl\WyndHnvckBufXSjboSgZZN{\XO\|ZXSgZZMh\WG{bImgZZBweHSxdHnjJINmdGy\|IHH0JFMhfU1iYX\0[ZIhOjRiaILzJIJ6KEGwbnX4bY4hXi2ISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkhMFK4YjC9JFEvOzRidH:gNU43PyVr	NV3OV2ZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
NCI-H1975	NFzudG5HfW6ldHnvckBie3OjeR?=				NFXx[ZNKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGG2IEGgeI8hOTByIH7NJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R?	NHLUXIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUmwOlEyPCd-Mkm5NFYyOTR:L3G+
A431	NIfYS3pHfW6ldHnvckBie3OjeR?=				MXjT[Yxm[3Srdnn0fUBz[XSrbzygdoF1cW9iSVO1NEBnd3JiaIXtZY4hSTR\|MTDj[YxteyCxdnXy[ZhxemW\|c3nu[{B4cWymLYT5dIUhTUeIUjD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNM2w5PTiUIH31eIFvfA>?	NXz1fpV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|E3OzlpPkK3NVMyPjN7PD;hQi=>
PC9	NGS5NWFCdnSrdIXtc5Ih[WO2aY\peJkh[XO\|YYm=				MnPjRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCBzMDDt[{9s\y:mYYmsJJBwKHGmIH\vdkA4KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
A431	M1TTc2FvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				M3\QZmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0N\|Eh[2WubIOgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEA2KG2pL3vnM4RigSxicH:gdYQh\m:{IEeg[IF6eyC{ZXzheIl3\SC2bzDjc451em:u	Mo\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / p-AKT / p-ERK; PubMed: 28416483 Cancer Res PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib. ABCB1; PubMed: 27649127 Molecules The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.	28416483 27649127
Growth inhibition assay	Cell viability; PubMed: 31043587 Cell Death Dis Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. P < 0.05, P < 0.01, **P < 0.005 by t-test.	31043587
Immunofluorescence	Ki67 / γH2AX / p16; PubMed: 29212784 EMBO Mol Med PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. P ≤ 0.01, *P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.	29212784

体内研究

AZD9291（5mg / kg p.o.）引起整个EGFRm+（PC9）和EGFRm+/ T790M（H1975）肿瘤模型肿瘤中显著的肿瘤消退，伴随着对体内EGFR磷酸化和下游关键信号通路，如AKT和ERK的显著抑制。^[2]

动物实验： ^[2]	- 合并 Animal Models: PC9和H1975移植瘤小鼠 Dosages: ~5 毫克/千克 Administration: p.o. (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	99 mg/mL warmed (198.15 mM)
	Water	Insoluble
	Ethanol	'43 mg/mL warmed
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	7.5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Osimertinib (AZD9291) SDF

分子量	499.61
化学式	C₂₈ H₃₃ N₇ O₂
CAS号	1421373-65-0
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Mereletinib

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02841579	Completed	Drug: Osimertinib	Non-Small Cell Lung Cancer	MedSIR\|AstraZeneca	August 2016	Phase 2
NCT02771314	Active not recruiting	Drug: AZD9291	Non Small Cell Lung Cancer	Hellenic Oncology Research Group	August 2 2016	Phase 2
NCT02511106	Active not recruiting	Drug: AZD9291 80 mg/40 mg\|Drug: Placebo AZD9291 80 mg/40 mg	Stage IB-IIIA Non-small Cell Lung Carcinoma	AstraZeneca	October 21 2015	Phase 3
NCT02529995	Completed	Drug: AZD9291 40 mg\|Drug: AZD9291 80 mg	Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive	AstraZeneca	August 24 2015	Phase 1
NCT02491944	Completed	Drug: AZD9291\|Drug: [14C]AZD9291	Oncology	AstraZeneca	July 2015	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?
回答：
Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

研究领域

产品类型

定制您的化合物库

Osimertinib (AZD9291)

客户使用Selleck生产的Osimertinib (AZD9291)发表文献225篇：

产品安全说明书

EGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Osimertinib (AZD9291) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

常见问题及建议解决方法

EGFR Signaling Pathway Map

相关EGFR产品